Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Morgan Stanley strategists highlighted companies that look likely to impress with earnings including Chewy, Eaton, Nvidia, ...

Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

The move reveals both the power of philanthropic groups to sway legislators and a split in the administration’s coalition.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

S&P 500, Microsoft Corporation, Eli Lilly and Company, Alphabet Inc Class A. Read 's Market Analysis on Investing.com ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

Eli Lilly has a forward revenue growth rate of approximately 30%, and a forward diluted earnings per share growth rate of approximately 70%; these are incredible numbers.

Macquarie Asset Management, an investment management company, released its “Macquarie Large Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.